$0.67
3.49% yesterday
Nasdaq, Jun 13, 10:04 pm CET
ISIN
US5288723027
Symbol
LXRX
Sector
Industry

Lexicon Pharmaceuticals, Inc. Stock price

$0.67
+0.04 6.59% 1M
-0.14 17.13% 6M
-0.07 9.07% YTD
-1.16 63.31% 1Y
-1.22 64.47% 5Y
-7.23 91.50% 10Y
-29.64 97.78% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.02 3.49%
ISIN
US5288723027
Symbol
LXRX
Sector
Industry

Key metrics

Market capitalization $252.70m
Enterprise Value $158.56m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.08
P/S ratio (TTM) P/S ratio 8.10
P/B ratio (TTM) P/B ratio 2.05
Revenue growth (TTM) Revenue growth 1,239.48%
Revenue (TTM) Revenue $31.21m
EBIT (operating result TTM) EBIT $-177.46m
Free Cash Flow (TTM) Free Cash Flow $-167.43m
Cash position $194.84m
EPS (TTM) EPS $-0.48
P/E forward negative
P/S forward 15.73
EV/Sales forward 9.87
Short interest 29.88%
Show more

Is Lexicon Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Lexicon Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Lexicon Pharmaceuticals, Inc. forecast:

2x Buy
50%
2x Hold
50%

Analyst Opinions

4 Analysts have issued a Lexicon Pharmaceuticals, Inc. forecast:

Buy
50%
Hold
50%

Financial data from Lexicon Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
31 31
1,239% 1,239%
100%
- Direct Costs 0.62 0.62
520% 520%
2%
31 31
1,272% 1,272%
98%
- Selling and Administrative Expenses 123 123
3% 3%
393%
- Research and Development Expense 85 85
39% 39%
274%
-177 -177
5% 5%
-567%
- Depreciation and Amortization 0.57 0.57
5% 5%
2%
EBIT (Operating Income) EBIT -177 -177
5% 5%
-569%
Net Profit -177 -177
8% 8%
-568%

In millions USD.

Don't miss a Thing! We will send you all news about Lexicon Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lexicon Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
16 days ago
THE WOODLANDS, Texas, May 29, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference, taking place in New York City on Thursday, June 5 at 12:50 p.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company's ...
Neutral
GlobeNewsWire
26 days ago
Lexicon is evaluating the safety and efficacy of sotagliflozin in patients with both obstructive and  non-obstructive hypertrophic cardiomyopathy (HCM) Pivotal Phase 3 clinical trial is actively enrolling patients in 20 countries, with all sites expected to be operational by Q3 2025 THE WOODLANDS, Texas, May 19, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announc...
Neutral
Seeking Alpha
about one month ago
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ET Company Participants Lisa DeFrancesco - Senior Vice President, Investor Relations and Corporate Strategy Mike Exton - Chief Executive Officer and Director Scott Coiante - Senior Vice President and Chief Financial Officer Craig Granowitz - Senior Vice President and Chief Medical Officer Conferen...
More Lexicon Pharmaceuticals, Inc. News

Company Profile

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include XERMELO, Zynquista, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Head office United States
CEO Michael Exton
Employees 103
Founded 1995
Website www.lexpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today